Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations.

about

Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations.

Item

http://www.wikidata.org/entity/Q54984374

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Cost-Effectiveness of Treatmen ...... in non-VA and VA Populations.

@en

Cost-Effectiveness of Treatmen ...... in non-VA and VA Populations.

@nl

type

Item

label

Cost-Effectiveness of Treatmen ...... in non-VA and VA Populations.

@en

Cost-Effectiveness of Treatmen ...... in non-VA and VA Populations.

@nl

prefLabel

Cost-Effectiveness of Treatmen ...... in non-VA and VA Populations.

@en

Cost-Effectiveness of Treatmen ...... in non-VA and VA Populations.

@nl

P1476

Cost-Effectiveness of Treatmen ...... in non-VA and VA Populations.

@en

P2093

Douglas K Owens

http://www.w3.org/2001/XMLSchema#string

Jeanie Lo

http://www.w3.org/2001/XMLSchema#string

Paul G Barnett

http://www.w3.org/2001/XMLSchema#string

Risha Gidwani

http://www.w3.org/2001/XMLSchema#string

Shan Liu

http://www.w3.org/2001/XMLSchema#string

Steven M Asch

http://www.w3.org/2001/XMLSchema#string

Vilija R Joyce

http://www.w3.org/2001/XMLSchema#string

P2860

Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

Sofosbuvir for previously untreated chronic hepatitis C infection

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

Boceprevir for untreated chronic HCV genotype 1 infection

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force.

Empirically calibrated model of hepatitis C virus infection in the United States.

P31

scholarly article

P356

10.1177/2381468316671946

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mark Holodniy

Jeremy Goldhaber-Fiebert

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29756049

http://www.w3.org/2001/XMLSchema#string

P932

5942888

http://www.w3.org/2001/XMLSchema#string